MIN-101 + Placebo
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 19/100
19
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Schizophrenia
Conditions
Schizophrenia
Trial Timeline
Sep 1, 2014 → Feb 1, 2015
NCT ID
NCT02232529About MIN-101 + Placebo
MIN-101 + Placebo is a phase 1 stage product being developed by Minerva Neurosciences for Schizophrenia. The current trial status is completed. This product is registered under clinical trial identifier NCT02232529. Target conditions include Schizophrenia.
What happened to similar drugs?
20 of 20 similar drugs in Schizophrenia were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02232529 | Phase 1 | Completed |
Competing Products
20 competing products in Schizophrenia